Spirepoint Private Client LLC Raises Holdings in Eli Lilly and Company $LLY

Spirepoint Private Client LLC raised its position in Eli Lilly and Company (NYSE:LLY) by 4.3% during the third quarter, HoldingsChannel reports. The firm owned 16,852 shares of the company’s stock after purchasing an additional 696 shares during the period. Eli Lilly and Company comprises 1.4% of Spirepoint Private Client LLC’s holdings, making the stock its 17th biggest position. Spirepoint Private Client LLC’s holdings in Eli Lilly and Company were worth $12,858,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of LLY. Vanguard Group Inc. boosted its position in Eli Lilly and Company by 1.5% during the second quarter. Vanguard Group Inc. now owns 80,407,430 shares of the company’s stock worth $62,680,004,000 after acquiring an additional 1,183,038 shares during the last quarter. Laurel Wealth Advisors LLC lifted its stake in Eli Lilly and Company by 78,621.2% in the 2nd quarter. Laurel Wealth Advisors LLC now owns 11,552,336 shares of the company’s stock worth $9,005,392,000 after purchasing an additional 11,537,661 shares in the last quarter. Norges Bank acquired a new position in shares of Eli Lilly and Company during the 2nd quarter worth approximately $8,827,714,000. Jennison Associates LLC grew its position in shares of Eli Lilly and Company by 4.3% in the second quarter. Jennison Associates LLC now owns 5,447,636 shares of the company’s stock valued at $4,246,596,000 after purchasing an additional 226,620 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its holdings in shares of Eli Lilly and Company by 2.0% in the second quarter. Charles Schwab Investment Management Inc. now owns 5,359,653 shares of the company’s stock valued at $4,178,010,000 after purchasing an additional 103,119 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Analyst Upgrades and Downgrades

LLY has been the topic of a number of recent research reports. CICC Research boosted their price objective on Eli Lilly and Company from $801.00 to $1,060.00 and gave the stock a “neutral” rating in a research note on Thursday, November 13th. Leerink Partners set a $1,234.00 price objective on shares of Eli Lilly and Company in a report on Monday. Truist Financial lifted their target price on shares of Eli Lilly and Company from $1,038.00 to $1,182.00 and gave the stock a “buy” rating in a research note on Wednesday, November 19th. Sanford C. Bernstein reiterated an “outperform” rating on shares of Eli Lilly and Company in a report on Friday, December 19th. Finally, Daiwa Capital Markets set a $1,230.00 price target on shares of Eli Lilly and Company and gave the company a “buy” rating in a research note on Tuesday, December 16th. Five equities research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $1,169.00.

Eli Lilly and Company Trading Up 4.1%

LLY opened at $1,107.54 on Thursday. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,117.66. The company has a quick ratio of 1.24, a current ratio of 1.55 and a debt-to-equity ratio of 1.71. The business has a fifty day simple moving average of $1,028.26 and a 200-day simple moving average of $856.98. The firm has a market cap of $1.05 trillion, a P/E ratio of 54.18, a P/E/G ratio of 0.77 and a beta of 0.35.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The firm had revenue of $17.60 billion for the quarter, compared to the consensus estimate of $16.09 billion. During the same quarter in the previous year, the business earned $1.18 EPS. The company’s quarterly revenue was up 53.9% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, equities analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be given a dividend of $1.73 per share. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, February 13th. Eli Lilly and Company’s dividend payout ratio is currently 33.86%.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly confirmed it will buy Ventyx Biosciences in an all-cash deal worth about $1.2 billion, gaining a pipeline of oral small-molecule NLRP3 inhibitors and inflammatory disease candidates that expand Lilly beyond diabetes/weight-loss. This acquisition is a clear pipeline/strategic positive. Eli Lilly to buy Ventyx Biosciences in $1.2 billion deal
• Positive Sentiment: Lilly expanded its obesity/metabolic pipeline via a multiyear partnership/licensing deal with Nimbus (reported value ~$1.3B), adding an oral obesity candidate to its development portfolio — another growth pathway beyond injectables. Boston biotech Nimbus to partner with Eli Lilly on weight-loss pill in $1.3 billion deal
• Positive Sentiment: Lilly struck a collaboration with InduPro on a next-gen cancer program worth up to $950 million, strengthening oncology exposure and long-term revenue optionality. Lilly links up with InduPro in next-gen cancer treatment deal worth up to $950M
• Positive Sentiment: Clarivate named several Lilly cardiometabolic launches among drugs to watch for 2026, highlighting continued product catalysts beyond current blockbusters. Lilly’s prospective cardiometabolic launches dominate list of drugs to watch in 2026: Clarivate
• Positive Sentiment: Analysts are bullish: Citigroup flagged ~50% upside, and several upgrades/positive notes have circulated, supporting momentum and investor confidence in Lilly’s pipeline and earnings outlook. Eli Lilly Stock (LLY) Has 50% Upside, Says Citigroup
• Neutral Sentiment: The stock printed an all-time high intraday as buyers priced in the M&A and deal flow; that’s market confirmation of the reaction but not a new fundamental. Eli Lilly stock hits all-time high of 1113.03 USD
• Negative Sentiment: Lilly faces legal pressure: the Indiana attorney general sued alleging inflated insulin pricing, a regulatory and reputational overhang that could lead to fines, settlements or policy scrutiny. Indiana sues Eli Lilly alleging insulin price-fixing scheme

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.